BMJ open · 2016
Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study).
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Onozuka Daisuke, Hagihara Akihito, Nishimura Kunihiro, Kada Akiko, Nakagawara Jyoji, Ogasawara Kuniaki, Ono Junichi, Shiokawa Yoshiaki, Aruga Toru, Miyachi Shigeru, Nagata Izumi, Toyoda Kazunori, Matsuda Shinya, Suzuki Akifumi, Kataoka Hiroharu, Nakamura Fumiaki, Kamitani Satoru, Nishimura Ataru, Kurogi Ryota, Sayama Tetsuro, Iihara Koji, J-ASPECT Study Collaborators
Аннотация
OBJECTIVES: To elucidate the association between antiplatelet use in patients with non-haemorrhagic moyamoya disease before hospital admission and good functional status on admission in Japan.
DESIGN: Retrospective, multicentre, non-randomised, observational study.
SETTING: Nationwide registry data in Japan.
PARTICIPANTS: A total of 1925 patients with non-haemorrhagic moyamoya disease admitted between 1 April 2012 and 31 March 2014 in Japan.
MAIN OUTCOME MEASURE: We performed propensity score-matched analysis to examine the association between prehospital antiplatelet use and no significant disability on hospital admission, as defined by a modified Rankin Scale score of 0 or 1.
RESULTS: Propensity-matched patients who received prehospital antiplatelet drugs were associated with a good outcome on hospital admission (OR adjusted for all covariates, 3.82; 95% CI 1.22 to 11.99) compared with those who did not receive antiplatelet drugs prior to hospital admission.
CONCLUSIONS: Prehospital antiplatelet use was significantly associated with good functional status on hospital admission among patients with non-haemorrhagic moyamoya disease in Japan. Our results suggest that prehospital antiplatelet use should be considered when evaluating outcomes of patients with non-haemorrhagic moyamoya disease.
DESIGN: Retrospective, multicentre, non-randomised, observational study.
SETTING: Nationwide registry data in Japan.
PARTICIPANTS: A total of 1925 patients with non-haemorrhagic moyamoya disease admitted between 1 April 2012 and 31 March 2014 in Japan.
MAIN OUTCOME MEASURE: We performed propensity score-matched analysis to examine the association between prehospital antiplatelet use and no significant disability on hospital admission, as defined by a modified Rankin Scale score of 0 or 1.
RESULTS: Propensity-matched patients who received prehospital antiplatelet drugs were associated with a good outcome on hospital admission (OR adjusted for all covariates, 3.82; 95% CI 1.22 to 11.99) compared with those who did not receive antiplatelet drugs prior to hospital admission.
CONCLUSIONS: Prehospital antiplatelet use was significantly associated with good functional status on hospital admission among patients with non-haemorrhagic moyamoya disease in Japan. Our results suggest that prehospital antiplatelet use should be considered when evaluating outcomes of patients with non-haemorrhagic moyamoya disease.